Capricor Therapeutics Q3 net loss widens

Capricor Therapeutics

10/11/2025 21:16

Overview

Capricor Q3 net loss widens to $24.6 mln, with no revenue generated

Company prepares for Deramiocel launch in 2026, pending HOPE-3 study results

Cash balance of $99 mln expected to support operations into Q4 2026

Outlook

Capricor expects HOPE-3 Phase 3 study results in Q4 2025

Company plans commercial launch of Deramiocel in 2026

Capricor expects cash balance to support operations into Q4 2026

Result Drivers

HOPE-3 RESULTS - Capricor anticipates topline results from HOPE-3 Phase 3 trial for Deramiocel in Q4 2025, which could lead to BLA resubmission

COMMERCIAL PREPARATIONS - Capricor is preparing for potential Deramiocel launch in 2026, pending approval, with manufacturing readiness confirmed

STEALTHX VACCINE TRIAL - Phase 1 trial of StealthX™ exosome-based vaccine ongoing, with initial data expected Q1 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.54
Q3 Net Income
-$24.60 mln
Q3 Basic EPS
-$0.54
Q3 Operating Expenses
$26.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Capricor Therapeutics Inc is $21.50, about 72.4% above its November 7 closing price of $5.93

Press Release: ID:nGNX4Yc4K5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)